292 related articles for article (PubMed ID: 20091131)
21. Immunohistochemistry for 2-Succinocysteine (2SC) and Fumarate Hydratase (FH) in Cutaneous Leiomyomas May Aid in Identification of Patients With HLRCC (Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome).
Buelow B; Cohen J; Nagymanyoki Z; Frizzell N; Joseph NM; McCalmont T; Garg K
Am J Surg Pathol; 2016 Jul; 40(7):982-8. PubMed ID: 26945337
[TBL] [Abstract][Full Text] [Related]
22. Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.
Kamai T; Abe H; Arai K; Murakami S; Sakamoto S; Kaji Y; Yoshida KI
BMC Cancer; 2016 Mar; 16():232. PubMed ID: 26983443
[TBL] [Abstract][Full Text] [Related]
23. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry.
Chen YB; Brannon AR; Toubaji A; Dudas ME; Won HH; Al-Ahmadie HA; Fine SW; Gopalan A; Frizzell N; Voss MH; Russo P; Berger MF; Tickoo SK; Reuter VE
Am J Surg Pathol; 2014 May; 38(5):627-37. PubMed ID: 24441663
[TBL] [Abstract][Full Text] [Related]
24. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency.
Alam NA; Rowan AJ; Wortham NC; Pollard PJ; Mitchell M; Tyrer JP; Barclay E; Calonje E; Manek S; Adams SJ; Bowers PW; Burrows NP; Charles-Holmes R; Cook LJ; Daly BM; Ford GP; Fuller LC; Hadfield-Jones SE; Hardwick N; Highet AS; Keefe M; MacDonald-Hull SP; Potts ED; Crone M; Wilkinson S; Camacho-Martinez F; Jablonska S; Ratnavel R; MacDonald A; Mann RJ; Grice K; Guillet G; Lewis-Jones MS; McGrath H; Seukeran DC; Morrison PJ; Fleming S; Rahman S; Kelsell D; Leigh I; Olpin S; Tomlinson IP
Hum Mol Genet; 2003 Jun; 12(11):1241-52. PubMed ID: 12761039
[TBL] [Abstract][Full Text] [Related]
25. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency.
Bayley JP; Launonen V; Tomlinson IP
BMC Med Genet; 2008 Mar; 9():20. PubMed ID: 18366737
[TBL] [Abstract][Full Text] [Related]
26. In deep bioinformatic characterization of a novel fumarate hydratase variant FH c.199T > G; (p.Tyr67Asp) in hereditary leiomyomatosis and renal cell carcinoma.
Chami A; de Souza Zózimo TR; Alves TM; Matosinho CGR; Santos C; Simões MM; Cabral WLR; de Paula Ricardo BF; da Silva Filho AL; Carvalho MRS; da Conceição Braga L
Fam Cancer; 2023 Oct; 22(4):481-486. PubMed ID: 37316640
[TBL] [Abstract][Full Text] [Related]
27. Uterine leiomyomas in hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome can be identified through distinct clinical characteristics and typical morphology.
Uimari O; Ahtikoski A; Kämpjärvi K; Butzow R; Järvelä IY; Ryynänen M; Aaltonen LA; Vahteristo P; Kuismin O
Acta Obstet Gynecol Scand; 2021 Nov; 100(11):2066-2075. PubMed ID: 34480341
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients.
Choi Y; Keam B; Kim M; Yoon S; Kim D; Choi JG; Seo JY; Park I; Lee JL
Cancer Res Treat; 2019 Oct; 51(4):1549-1556. PubMed ID: 30913859
[TBL] [Abstract][Full Text] [Related]
29. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma.
Gardie B; Remenieras A; Kattygnarath D; Bombled J; Lefèvre S; Perrier-Trudova V; Rustin P; Barrois M; Slama A; Avril MF; Bessis D; Caron O; Caux F; Collignon P; Coupier I; Cremin C; Dollfus H; Dugast C; Escudier B; Faivre L; Field M; Gilbert-Dussardier B; Janin N; Leport Y; Leroux D; Lipsker D; Malthieu F; McGilliwray B; Maugard C; Méjean A; Mortemousque I; Plessis G; Poppe B; Pruvost-Balland C; Rooker S; Roume J; Soufir N; Steinraths M; Tan MH; Théodore C; Thomas L; Vabres P; Van Glabeke E; Meric JB; Verkarre V; Lenoir G; Joulin V; Deveaux S; Cusin V; Feunteun J; Teh BT; Bressac-de Paillerets B; Richard S;
J Med Genet; 2011 Apr; 48(4):226-34. PubMed ID: 21398687
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of somatic and germline mutations of Fumarate hydratase in uterine leiomyomas from young patients.
Liu C; Dillon J; Beavis AL; Liu Y; Lombardo K; Fader AN; Hung CF; Wu TC; Vang R; Garcia JE; Xing D
Histopathology; 2020 Feb; 76(3):354-365. PubMed ID: 31564060
[TBL] [Abstract][Full Text] [Related]
31. Germline Whole-Gene Deletion of FH Diagnosed from Tumor Profiling.
Ueki A; Sugano K; Misu K; Aimono E; Nakamura K; Tanishima S; Tanaka N; Mikami S; Hirasawa A; Ando M; Yoshida T; Oya M; Nishihara H; Kosaki K
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360727
[TBL] [Abstract][Full Text] [Related]
32. Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing.
Lu E; Hatchell KE; Nielsen SM; Esplin ED; Ouyang K; Nykamp K; Zavoshi S; Li S; Zhang L; Wilde BR; Christofk HR; Boutros PC; Shuch B
Cancer; 2022 Feb; 128(4):675-684. PubMed ID: 34724198
[TBL] [Abstract][Full Text] [Related]
33. A retrospective review of 48 individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC).
Bhola PT; Gilpin C; Smith A; Graham GE
Fam Cancer; 2018 Oct; 17(4):615-620. PubMed ID: 29423582
[TBL] [Abstract][Full Text] [Related]
34. Conventional renal cancer in a patient with fumarate hydratase mutation.
Lehtonen HJ; Blanco I; Piulats JM; Herva R; Launonen V; Aaltonen LA
Hum Pathol; 2007 May; 38(5):793-6. PubMed ID: 17270241
[TBL] [Abstract][Full Text] [Related]
35. Hereditary leiomyomatosis and renal cell carcinoma syndrome associated uterine smooth muscle tumors: Bridging morphology and clinical screening.
Garg K; Rabban J
Genes Chromosomes Cancer; 2021 Mar; 60(3):210-216. PubMed ID: 33099845
[TBL] [Abstract][Full Text] [Related]
36. Fumarate Hydratase is a Novel Gene for Familial Non-Medullary Thyroid Cancer.
Alzahrani AS; Alswailem M; Alghamdi B; Al-Hindi H
J Clin Endocrinol Metab; 2022 Aug; 107(9):2539-2544. PubMed ID: 35751867
[TBL] [Abstract][Full Text] [Related]
37. Segregation, immunohistochemical, molecular and functional analyses classify a novel missense variant in fumarate hydratase (FH) as pathogenic.
Ouchene L; Wilde B; Chan-Pak-Choon F; Camacho Valenzuela J; Brimo F; Witkowski L; Christofk H; Domecq C; Fu L; Weber E; Lemieux Anglin B; Netchiporouk E; Foulkes WD
Genes Chromosomes Cancer; 2024 Feb; 63(2):e23221. PubMed ID: 38682608
[TBL] [Abstract][Full Text] [Related]
38. Cryptic splice mutation in the fumarate hydratase gene in patients with clinical manifestations of Hereditary Leiomyomatosis and Renal Cell Cancer.
Crooks DR; Cawthon GM; Fitzsimmons CM; Perez M; Ricketts CJ; Vocke CD; Yang Y; Middelton L; Nielsen D; Schmidt LS; Tandon M; Merino MJ; Ball MW; Meier JL; Batista PJ; Linehan WM
Hum Mol Genet; 2023 Nov; 32(22):3135-3145. PubMed ID: 37561409
[TBL] [Abstract][Full Text] [Related]
39. Review of hereditary leiomyomatosis renal cell carcinoma with focus on clinical and pathobiological aspects of renal tumors.
Kuroda N; Ohe C; Kato I; Furuya M; Baba M; Nagashima Y; Nakatani Y; Murakami I; Zhou M; Michal M; He O; Amin MB
Pol J Pathol; 2017; 68(4):284-290. PubMed ID: 29517197
[TBL] [Abstract][Full Text] [Related]
40. Mutation screening of fumarate hydratase by multiplex ligation-dependent probe amplification: detection of exonic deletion in a patient with leiomyomatosis and renal cell cancer.
Ahvenainen T; Lehtonen HJ; Lehtonen R; Vahteristo P; Aittomäki K; Baynam G; Dommering C; Eng C; Gruber SB; Grönberg H; Harvima R; Herva R; Hietala M; Kujala M; Kääriäinen H; Sunde L; Vierimaa O; Pollard PJ; Tomlinson IP; Björck E; Aaltonen LA; Launonen V
Cancer Genet Cytogenet; 2008 Jun; 183(2):83-8. PubMed ID: 18503824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
